Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) – Research analysts at SunTrust Banks reduced their Q3 2017 earnings per share estimates for Bellicum Pharmaceuticals in a report issued on Tuesday. SunTrust Banks analyst P. Lawson now expects that the biopharmaceutical company will earn ($0.76) per share for the quarter, down from their prior forecast of ($0.70). SunTrust Banks also issued estimates for Bellicum Pharmaceuticals’ Q4 2017 earnings at ($0.79) EPS, FY2017 earnings at ($3.09) EPS, FY2018 earnings at ($2.77) EPS, FY2019 earnings at ($2.21) EPS, FY2020 earnings at ($0.99) EPS and FY2021 earnings at $0.98 EPS.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by $0.09. Bellicum Pharmaceuticals had a negative return on equity of 70.74% and a negative net margin of 17,957.31%. During the same period last year, the firm earned ($0.61) EPS.

COPYRIGHT VIOLATION WARNING: “SunTrust Banks Analysts Reduce Earnings Estimates for Bellicum Pharmaceuticals, Inc. (BLCM)” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/08/11/suntrust-banks-analysts-reduce-earnings-estimates-for-bellicum-pharmaceuticals-inc-blcm.html.

A number of other research firms have also commented on BLCM. Raymond James Financial, Inc. reaffirmed a “buy” rating on shares of Bellicum Pharmaceuticals in a report on Tuesday, June 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $35.00 price target on shares of Bellicum Pharmaceuticals in a report on Monday, June 26th. ValuEngine lowered Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday. Jefferies Group LLC cut their price target on Bellicum Pharmaceuticals from $19.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, May 9th. Finally, Ladenburg Thalmann Financial Services set a $31.00 price target on Bellicum Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, June 24th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $26.20.

Shares of Bellicum Pharmaceuticals (NASDAQ BLCM) opened at 7.65 on Friday. Bellicum Pharmaceuticals has a 12-month low of $7.59 and a 12-month high of $23.11. The company’s 50-day moving average price is $11.55 and its 200 day moving average price is $12.35. The firm’s market capitalization is $254.18 million.

In related news, VP Ken Moseley sold 13,823 shares of the stock in a transaction on Thursday, July 13th. The stock was sold at an average price of $12.26, for a total value of $169,469.98. Following the sale, the vice president now owns 14,314 shares in the company, valued at $175,489.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Alan A. Musso sold 6,311 shares of the stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $12.24, for a total value of $77,246.64. The disclosure for this sale can be found here. Insiders sold 30,571 shares of company stock worth $367,295 in the last quarter. 23.30% of the stock is currently owned by company insiders.

Several large investors have recently modified their holdings of the company. Principal Financial Group Inc. increased its stake in shares of Bellicum Pharmaceuticals by 0.7% in the first quarter. Principal Financial Group Inc. now owns 83,338 shares of the biopharmaceutical company’s stock worth $1,029,000 after buying an additional 610 shares during the period. American International Group Inc. increased its stake in shares of Bellicum Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 12,902 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 852 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Bellicum Pharmaceuticals by 1.0% in the first quarter. Bank of New York Mellon Corp now owns 95,934 shares of the biopharmaceutical company’s stock worth $1,184,000 after buying an additional 935 shares during the period. Teachers Advisors LLC increased its stake in shares of Bellicum Pharmaceuticals by 5.5% in the fourth quarter. Teachers Advisors LLC now owns 35,608 shares of the biopharmaceutical company’s stock worth $485,000 after buying an additional 1,844 shares during the period. Finally, ProShare Advisors LLC increased its stake in shares of Bellicum Pharmaceuticals by 14.9% in the second quarter. ProShare Advisors LLC now owns 19,393 shares of the biopharmaceutical company’s stock worth $227,000 after buying an additional 2,513 shares during the period. Institutional investors own 64.76% of the company’s stock.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Earnings History and Estimates for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.